الفهرس 
COVEROnly 14 pages are availabe for public view
 |  | from | 74 |  |  |
| | | from | 74 | | |
Abstract
Pathological myopia is one of the leading causes of visual disability in the world from 20 to 50 years of age.
Prevalence rates of Pathological myopia vary between 2% and 9%, depending on the race and age of the population. It is characterized by axial length more than 26.5 mm with secondary degenerative changes of the sclera, choroid, Bruch membrane, retinal pigment epithelium and retina.
The most common posterior pole changes include posterior staphyloma, optic nerve crescents, chorioretinal atrophy, lacquer cracks, and the development of choroidal neovascularization in the center of the macula via vascular endothelial growth factor modulation
Choroidal neovascularization (CNV) is one of the most important vision-threatening complications of Pathological myopia and occurs in 5% to 10% of myopic patients.
Choroidal neovascularization in Pathological myopia has been treated with different approaches that include: laser photocoagulation, submacular surgery, photodynamic therapy, and more recently intravitreal injections of anti-Vascular Endothelial Growth Factor drugs.
Different studies assessed the efficacy of anti-VGEF versus photodynamic therapy for CNV associated with pathological myopia depending on the difference in the visual outcome, the CNV regression pattern and the rate of development of chorioretinal atrophy.
These studies concluded that Anti- VEGFs have advantages superior to PDT due to:
1-The anti-VEGF therapy showed significant postoperative improvement in visual acuity compared with the PDT.
2-Chorioretinal atrophy developed significantly more frequently in PDT-treated than Anti- VEGF-treated eyes.
3-The CNVs that had an angiographic closure were accompanied by shrinkage of CNV in the Anti- VEGF-treated eyes, whereas the CNV size did not decrease, or even increased PDT-treated eyes.